Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Purine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.35 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.32 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.32 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 0.32 |
| ▸ | EGFR known ✓ | P00533 | 3/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM4B | O94953 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Purine SCHEMBL1150716 | 1.00 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL12003982 | 0.98 | KDM4A (0.36) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL6421376 | 0.98 | KDM4A (0.38) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL3157 | 0.98 | — | — | |
| Purine SCHEMBL29456595 | 0.98 | — | — | |
| Purine SCHEMBL2120547 | 0.98 | KDM4A (0.38) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL6438162 | 0.95 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL1389668 | 0.95 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL9057416 | 0.95 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL5611476 | 0.95 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1143858-C | 6, 9-disubstituted 2- [ trans- (aminocyclohexyl) amino ] purines, compositions and uses thereof | ������ҩ������˾ | 2004-03-31 | — | — | CN | claimed |
| CN-1128149-C | 6,9-Disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTIS PHARMA INC (US) | 2003-11-19 | — | — | CN | claimed |
| CN-1292789-A | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AWANDIS PHARMACEUTICAL CORP (US) | 2001-04-25 | — | — | CN | claimed |
| CN-1291983-A | 6,9-Disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTIS PHARMA INC (US) | 2001-04-18 | — | — | CN | claimed |
| CN-108271917-A | Rice protein replenishers | 艾斯姆食品公司 | 2018-07-13 | — | — | CN | disclosed |
| CN-105101812-B | Rice protein supplement | 艾斯姆食品公司 | 2018-04-10 | — | — | CN | disclosed |
| CN-105101812-A | Rice protein supplement | AXIOM FOODS INC | 2015-11-25 | — | — | CN | disclosed |
| CN-102459272-A | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use | GENENTECH INC | 2012-05-16 | — | — | CN | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| CN-1143858-C | 6, 9-disubstituted 2- [ trans- (aminocyclohexyl) amino ] purines, compositions and uses thereof | ������ҩ������˾ | 2004-03-31 | — | — | CN | disclosed |
| WO-2000059449-A2 | PURINE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITION ACTIVITY | EURO-CELTIQUE S.A. (LU) | 2000-10-12 | — | — | WO | disclosed |
| CN-1269801-A | Purine acyclonucleosides as antiviral agents | COMMW SCIENT IND RES ORG (AU) | 2000-10-11 | — | — | CN | disclosed |
| CN-1232466-A | Phosphonate-nucleotide compounds | MITSUBISHI CHEM CORP (JP) | 1999-10-20 | — | — | CN | disclosed |
| US-5939422-A | AN ENZYME INHIBITOR AS BRONCHODILATOR, RELAXANTS, ANTIINFLAMMATORY AGENT FOR TREATING ASTHMA, ALLERGIES, INFLAMMATION, DEPRESSION, DEMENTIA, DISEASES ASSOCIATED WITH ABNORMAL HIGH LEVEL OF CYTOKINE | EURO-CELTIQUE, S.A. (LU) | 1999-08-17 | — | — | US | disclosed |
| EP-0916672-A1 | 6-Amino purine derivatives having PDE-IV inhibition activity and intermediates | Euroceltique S.A. (LU) | 1999-05-19 | — | — | EP | disclosed |
| EP-0916673-A1 | 6-Amino purine derivatives having PDE-IV inhibition activity | Euroceltique S.A. (LU) | 1999-05-19 | — | — | EP | disclosed |
| EP-0705265-A1 | NOVEL CHEMICAL COMPOUNDS HAVING PDE-IV INHIBITION ACTIVITY | Euroceltique S.A. (LU) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000516-A1 | NOVEL CHEMICAL COMPOUNDS HAVING PDE-IV INHIBITION ACTIVITY | EURO-CELTIQUE S.A. (LU) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | PTGS1 3152/4885GLA 4252/4885GAA 1107/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | PTGS1 3152/4885GLA 4252/4885GAA 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.